178 related articles for article (PubMed ID: 29872321)
1. Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma.
Lin M; Lv D; Zheng Y; Wu M; Xu C; Zhang Q; Wu L
Onco Targets Ther; 2018; 11():3101-3110. PubMed ID: 29872321
[TBL] [Abstract][Full Text] [Related]
2. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2.
Lu X; Zhang X; Zhang Y; Zhang K; Zhan C; Shi X; Li Y; Zhao J; Bai Y; Wang Y; Nie H; Li Y
Mol Carcinog; 2019 May; 58(5):749-759. PubMed ID: 30604893
[TBL] [Abstract][Full Text] [Related]
3. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
Fujiwara N; Nakagawa H; Enooku K; Kudo Y; Hayata Y; Nakatsuka T; Tanaka Y; Tateishi R; Hikiba Y; Misumi K; Tanaka M; Hayashi A; Shibahara J; Fukayama M; Arita J; Hasegawa K; Hirschfield H; Hoshida Y; Hirata Y; Otsuka M; Tateishi K; Koike K
Gut; 2018 Aug; 67(8):1493-1504. PubMed ID: 29437870
[TBL] [Abstract][Full Text] [Related]
4. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
5. CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer.
Zhang X; Zhang Z; Liu S; Li J; Wu L; Lv X; Xu J; Chen B; Zhao S; Yang H
Transl Oncol; 2021 Apr; 14(4):101023. PubMed ID: 33486313
[TBL] [Abstract][Full Text] [Related]
6. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.
Pan QZ; Pan K; Weng DS; Zhao JJ; Zhang XF; Wang DD; Lv L; Jiang SS; Zheng HX; Xia JC
Mol Carcinog; 2015 Aug; 54(8):598-607. PubMed ID: 24375474
[TBL] [Abstract][Full Text] [Related]
7. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
8. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
González-Romero F; Mestre D; Aurrekoetxea I; O'Rourke CJ; Andersen JB; Woodhoo A; Tamayo-Caro M; Varela-Rey M; Palomo-Irigoyen M; Gómez-Santos B; de Urturi DS; Núñez-García M; García-Rodríguez JL; Fernández-Ares L; Buqué X; Iglesias-Ara A; Bernales I; De Juan VG; Delgado TC; Goikoetxea-Usandizaga N; Lee R; Bhanot S; Delgado I; Perugorria MJ; Errazti G; Mosteiro L; Gaztambide S; Martinez de la Piscina I; Iruzubieta P; Crespo J; Banales JM; Martínez-Chantar ML; Castaño L; Zubiaga AM; Aspichueta P
Cancer Res; 2021 Jun; 81(11):2874-2887. PubMed ID: 33771899
[TBL] [Abstract][Full Text] [Related]
9. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic mechanisms contribute to decrease stearoyl-CoA desaturase 1 expression in the liver of dairy cows after prolonged feeding of high-concentrate diet.
Xu TL; Seyfert HM; Shen XZ
J Dairy Sci; 2018 Mar; 101(3):2506-2518. PubMed ID: 29274956
[TBL] [Abstract][Full Text] [Related]
11. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
12. SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma.
Huang J; Fan XX; He J; Pan H; Li RZ; Huang L; Jiang Z; Yao XJ; Liu L; Leung EL; He JX
Oncotarget; 2016 Jun; 7(26):39970-39979. PubMed ID: 27223066
[TBL] [Abstract][Full Text] [Related]
13. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
14. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
15. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis.
Li H; Chen Z; Zhang Y; Yuan P; Liu J; Ding L; Ye Q
Cancer Lett; 2021 Oct; 519():161-171. PubMed ID: 34303763
[TBL] [Abstract][Full Text] [Related]
16. Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma.
Bansal S; Berk M; Alkhouri N; Partrick DA; Fung JJ; Feldstein A
J Surg Res; 2014 Jan; 186(1):29-38. PubMed ID: 24135379
[TBL] [Abstract][Full Text] [Related]
17. Loss of tumor suppressive properties of lipid metabolism enzyme CPT2 in ovarian carcinoma: Comment on "CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer" by Zhang et al.
Vlachostergios PJ
Transl Oncol; 2021 Jul; 14(7):101067. PubMed ID: 33857744
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma.
Yang C; Wang S; Ruan H; Li B; Cheng Z; He J; Zuo Q; Yu C; Wang H; Lv Y; Gu D; Jin G; Yao M; Qin W; Jin H
J Cancer; 2019; 10(4):918-926. PubMed ID: 30854098
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
20. Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling.
Violante S; Ijlst L; van Lenthe H; de Almeida IT; Wanders RJ; Ventura FV
Biochim Biophys Acta; 2010 Sep; 1802(9):728-32. PubMed ID: 20538056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
